Bioventus Inc.
BVSHealthcareNASDAQMedical Devices · Last scanned May 29, 2026
Scan Results
Daily timeframe1 of 4 indicators bullish as of May 28
Part of the healthcare sector, Bioventus Inc. (BVS) is listed under Medical Devices. With a market capitalization of $600.9M, it sits in small-cap territory. The company's product portfolio includes pain treatments, which comprise various intra-articular and hyaluronic acid injections; peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis; and Stimrouter to treat chronic peripheral pain, and TalisMann provides stimulation to the targeted peripheral nerve, as well as XCELL PRP System, a benchtop device that processes whole blood to produce high-yield PRP with a 10-minute single-spin cycle.
Market Cap
$600.9M
Beta
0.72
P/E (TTM)
21.63
P/E (Fwd)
9.79
EPS (TTM)
$0.41
EPS (Fwd)
$0.91
ROE
16.5%
ROA
5.6%
Cash
$35.8M
Total Debt
$288.4M
Free CF
$63.3M
52W Change
36.9%
Annual Financials
Cash vs Debt
Bioventus Inc. carries $288.4M in total debt against $35.8M in cash reserves — debt is roughly 8.0x the cash position. Managing this leverage effectively will be important for long-term financial stability. The company generates $63.3M in free cash flow annually, which funds everything from R&D to shareholder returns without needing external financing. ROE of 16.5% points to strong capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. An ROA of 5.6% suggests reasonable efficiency in deploying the company's asset base. Revenue has been uneven over recent years, ranging from $512.1M to $568.1M.
Debt significantly exceeds cash reserves, which means the company's financial flexibility could be constrained during economic downturns. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Bioventus Inc. and its sector.